← Human Trials & Peer-Reviewed Studies
Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study.
Plain-language guide to PMID 17488793 (2007): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 17488793
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2007
- Study type
- Randomized Controlled Trial
- Authors
- Simon D et al. (5 authors)
- DOI
- 10.1210/jc.2006-2877
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
The objective of the study was to evaluate the impact on growth and body composition of rhGH started early after glucocorticoid initiation and to record adverse effects in children with JIA.
Why It Was Studied
Long-term glucocorticoid therapy adversely affects growth and body composition in children with juvenile idiopathic arthritis (JIA).
In previous studies, recombinant human GH (rhGH) halted the progression of these complications without inducing catch-up growth.
Who Took Part
By PubMed's age tags, the people studied were infants, young children and children, both men and women.
Thirty children, 12-15 months into glucocorticoid therapy for severe JIA, were enrolled.
How the Study Was Run
The researchers set it up as a randomized study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
This is a 3-yr randomized controlled study.
This study was conducted in a teaching hospital.
What Was Measured
The subject headings attached to it are Arthritis, Juvenile, Blood Glucose, Body Composition, Calcification, Physiologic, Glucocorticoids, Growth Disorders and Human Growth Hormone.
What This Means in Plain Language
The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2007 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.